ImmunityBio Stock Surges on Staggering Revenue Projections

ImmunityBio US45256X1037

Preliminary financial results for 2025 from ImmunityBio have sent shockwaves through the market. The biotechnology firm's revenue has skyrocketed, fueled by the rapid commercial adoption of its cancer therapy, Anktiva. This explosive growth has triggered a powerful rally in the company's share price, prompting investors to question whether this momentum is sustainable.

Beyond the impressive financial metrics, a series of critical regulatory victories are providing significant tailwinds for the stock. The Saudi Food and Drug Authority (SFDA) granted two landmark approvals for Anktiva. Notably, this included the world's first authorization for treating metastatic non-small cell lung cancer. Furthermore, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended conditional marketing authorization, paving the way for a launch across the European Union. These milestones dramatically expand the company's total addressable market.

Financial Firepower Supports Ambitions

Despite its aggressive commercial push, ImmunityBio maintains a robust financial position. As of December 31, 2025, the company held an estimated $242.8 million in cash, cash equivalents, and marketable securities. This substantial liquidity provides management with the resources to fund ongoing commercial expansion and upcoming clinical trials without imposing immediate dilution risks on existing shareholders. The investment narrative is consequently shifting from speculative potential to tangible commercial execution.

Revenue Metrics Demonstrate Unprecedented Scale

The catalyst for the current investor enthusiasm is the sheer velocity of commercial success. The company has announced preliminary net product sales for the full year 2025 of approximately $113 million. This represents a monumental increase of roughly 700% compared to the $14.15 million reported the previous year. The acceleration is particularly striking: fourth-quarter 2025 revenue reached about $38.3 million, marking a 20% sequential increase over the third quarter and year-over-year growth of 431%. The number of Anktiva units sold in 2025 surged by 750%.

Market participants now eagerly await the final audited annual results and, more importantly, the forward-looking guidance for 2026, which will offer clues about the longevity of this remarkable growth trajectory.